{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=20",
    "query": {
      "condition": "Refractory Malignancy",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 5765,
    "total_pages": 577,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T02:15:20.569Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02403271",
      "title": "A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Breast Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharmacyclics LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2015-03",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2019-01-03",
      "last_synced_at": "2026-11-12T02:15:20.569Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02403271"
    },
    {
      "nct_id": "NCT07705334",
      "title": "A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors",
        "Triple Negative Breast Cancer (TNBC)",
        "HR+ Breast Cancer",
        "Colon Cancer",
        "Gastric Cancer",
        "Hepatecellular Carcinoma",
        "NSCLC (Advanced Non-small Cell Lung Cancer)",
        "Mesothelioma",
        "Pancreatic Carcinoma Metastatic",
        "Hormone Refractory Prostate Cancer",
        "Soft Tissue Sarcomas"
      ],
      "interventions": [
        {
          "name": "SHY-ONC6",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SHY Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-06-24",
      "completion_date": "2028-05-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-11-12T02:15:20.569Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07705334"
    },
    {
      "nct_id": "NCT01161511",
      "title": "Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "XmAb5574",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2010-09",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2014-04-21",
      "last_synced_at": "2026-11-12T02:15:20.569Z",
      "location_count": 3,
      "location_summary": "Augusta, Georgia • Columbus, Ohio • Nashville, Tennessee",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01161511"
    },
    {
      "nct_id": "NCT01371630",
      "title": "Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1",
        "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative",
        "Burkitt-Like Lymphoma With 11q Aberration",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma, Not Otherwise Specified",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Recurrent Burkitt Lymphoma",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Refractory Burkitt Lymphoma"
      ],
      "interventions": [
        {
          "name": "Blinatumomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Inotuzumab Ozogamicin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 276,
      "start_date": "2011-08-26",
      "completion_date": "2027-12-25",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-11-12T02:15:20.569Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01371630"
    },
    {
      "nct_id": "NCT00562965",
      "title": "Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphoma, Follicular"
      ],
      "interventions": [
        {
          "name": "inotuzumab ozogamicin",
          "type": "DRUG"
        },
        {
          "name": "rituximab",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "vincristine",
          "type": "DRUG"
        },
        {
          "name": "prednisone/prednisolone",
          "type": "DRUG"
        },
        {
          "name": "mitoxantrone",
          "type": "DRUG"
        },
        {
          "name": "fludarabine",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2007-11",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2018-01-09",
      "last_synced_at": "2026-11-12T02:15:20.569Z",
      "location_count": 17,
      "location_summary": "Mission Hills, California • Evansville, Indiana • Baltimore, Maryland + 13 more",
      "locations": [
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Novi",
          "state": "Michigan"
        },
        {
          "city": "Southfield",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00562965"
    },
    {
      "nct_id": "NCT06624644",
      "title": "A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Melanoma (Skin Cancer)",
        "Melanoma Stage IIIB-IV",
        "Cutaneous Melanoma",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "LNS8801",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy (dacarbazine or temozolomide)",
          "type": "DRUG"
        },
        {
          "name": "Immunotherapy (Pembrolizumab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Immunotherapy (nivolumab and relatlimab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Immunotherapy (ipilimumab and nivolumab)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Linnaeus Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2025-08-06",
      "completion_date": "2031-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-11-12T02:15:20.569Z",
      "location_count": 9,
      "location_summary": "Newport Beach, California • San Francisco, California • Stanford, California + 6 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06624644"
    },
    {
      "nct_id": "NCT02092909",
      "title": "Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Waldenstrom's Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "IMO-8400",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Idera Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2014-03",
      "completion_date": "2017-11",
      "has_results": true,
      "last_update_posted_date": "2019-09-10",
      "last_synced_at": "2026-11-12T02:15:20.569Z",
      "location_count": 10,
      "location_summary": "Fayetteville, Arkansas • Los Angeles, California • Jacksonville, Florida + 7 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02092909"
    },
    {
      "nct_id": "NCT00048659",
      "title": "YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone-Refractory Prostate Cancer",
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "YM598",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": "2004-06",
      "has_results": false,
      "last_update_posted_date": "2012-06-07",
      "last_synced_at": "2026-11-12T02:15:20.569Z",
      "location_count": 14,
      "location_summary": "Anchorage, Alaska • San Bernardino, California • Torrance, California + 10 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "San Bernardino",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00048659"
    },
    {
      "nct_id": "NCT00050596",
      "title": "Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "MDX-010 / MDX-010 + Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": null,
      "start_date": "2002-11",
      "completion_date": "2004-11",
      "has_results": false,
      "last_update_posted_date": "2011-06-27",
      "last_synced_at": "2026-11-12T02:15:20.569Z",
      "location_count": 11,
      "location_summary": "Tucson, Arizona • Long Beach, California • San Diego, California + 7 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00050596"
    },
    {
      "nct_id": "NCT05985161",
      "title": "A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Wilms Tumor",
        "Rhabdoid Tumor",
        "Malignant Peripheral Nerve Sheath Tumors",
        "MPNST",
        "Nephroblastoma",
        "XPO1 Gene Mutation",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Selinexor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Months and older"
      },
      "enrollment_count": 45,
      "start_date": "2023-08-01",
      "completion_date": "2029-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-11-12T02:15:20.569Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05985161"
    }
  ]
}